Interleukin-5 (IL-5) is the key mediator for the function of eosinophil granulocytes, whose deregulation is characteristic of hypereosinophilic diseases and presumably contributes to allergic asthma. IL-5 signaling involves two transmembrane receptors, IL-5Ra and the common b chain, which upon formation of the ternary complex activate the JAK/STAT signaling cascade. To investigate the mechanism underlying ligand-receptor recognition, we determined the structure of IL-5 bound to the extracellular domain of IL-5Ra. IL-5 makes contact with all three fibronectin III-like domains of IL-5Ra, with the receptor architecture resembling a wrench. Mutagenesis data provide evidence that this wrench-like architecture is likely preformed. The structure demonstrates that for steric reasons, homodimeric IL-5 can bind only one receptor molecule, even though two equivalent receptor-binding sites exist. In regard to strong efforts being made to develop IL-5 antagonists for treating asthma and hypereosinophilic diseases, the advances in molecular understanding provided by this structure are of greatest value.
SUMMARY
Interleukin-5 (IL-5) is the key mediator for the function of eosinophil granulocytes, whose deregulation is characteristic of hypereosinophilic diseases and presumably contributes to allergic asthma. IL-5 signaling involves two transmembrane receptors, IL-5Ra and the common b chain, which upon formation of the ternary complex activate the JAK/STAT signaling cascade. To investigate the mechanism underlying ligand-receptor recognition, we determined the structure of IL-5 bound to the extracellular domain of IL-5Ra. IL-5 makes contact with all three fibronectin III-like domains of IL-5Ra, with the receptor architecture resembling a wrench. Mutagenesis data provide evidence that this wrench-like architecture is likely preformed. The structure demonstrates that for steric reasons, homodimeric IL-5 can bind only one receptor molecule, even though two equivalent receptor-binding sites exist. In regard to strong efforts being made to develop IL-5 antagonists for treating asthma and hypereosinophilic diseases, the advances in molecular understanding provided by this structure are of greatest value.
INTRODUCTION
Eosinophilia syndromes represent a heterogeneous class of disorders involving a largely increased number of eosinophils in the peripheral blood and/or a massive infiltration of eosinophils into certain tissues. This deregulation manifesting in the heart (endomyocardial fibrosis or Loeffler's endocarditis), brain, gastrointestinal tract (eosinophilic gastrointestinal diseases), or bone marrow results in tissue and organ damage (Klion, 2009) . It is the discharge of granular contents such as prostaglandins, leukotrienes, and reactive oxygen-producing enzymes, all powerful tools in the defense against worm pathogens, that accounts for tissue fibrosis in this particular context (Kariyawasam and Robinson, 2006) . However, the above-mentioned hypereosinophilic diseases are rare, but eosinophils' actions also seem to contribute to the pathology of asthma, characterized by airway obstruction and airway hyperresponsiveness to antigens or nonspecific triggers, associated with increased immunoglobulin production of the IgE class (atopy) (Kay, 2005) . Although the extent to which eosinophils may contribute to allergic asthma is still a matter of debate, their removal or attenuation is nevertheless considered a valuable strategy to counteract allergic asthma (Humbles et al., 2004; Lee et al., 2004) , opening the gates for therapeutic approaches involving interleukin-5 (IL-5). As IL-5 controls many aspects of eosinophil life from early differentiation of progenitor cells to migration, proliferation, as well as activation and survival (Takatsu and Nakajima, 2008) , it may not be surprising that in the past, various routes have been developed to neutralize IL-5 activity such as IL-5-neutralizing antibodies (Haldar et al., 2009) , peptides that compete for binding to the IL-5 receptor IL-5Ra (Ruchala et al., 2004) , or small molecules that bind to a free thiol group in the extracellular domain of the IL-5Ra receptor, thereby blocking IL-5 binding (Devos et al., 1994) .
Interleukin-5 is a homodimeric cytokine whose typical fourhelix bundle is unusually intertwined and stabilized by two interchain disulfide bonds (Milburn et al., 1993) . It binds with high affinity to the IL-5-specific IL-5Ra receptor. This intermediate complex then recruits the common b (bc) receptor (CD130) into a ternary complex. Similarly to receptor sharing observed for many interleukin ligand-receptor systems, the bc receptor is shared with interleukin-3 and granulocyte macrophage colony stimulation factor (GM-CSF) (Tavernier et al., 1991) . Mutagenesis studies performed on IL-5 and the receptor IL-5Ra have provided fruitful insights into the epitopes as well as the specificity of the underlying interaction (Cornelis et al., 1995; Graber et al., 1995; Ishino et al., 2004; Tavernier et al., 1995) , but on a molecular or atomic level important details are missing thus far due to the lack of structural data from IL-5 ligandreceptor complexes. In this study, we present the high-resolution crystal structure of IL-5 bound to the extracellular domain of its receptor IL-5Ra. In the complex, the extracellular domain of the IL-5 receptor wraps around IL-5 like a wrench around a nut. This new seemingly preformed receptor architecture has thus far only been seen for the rather distantly related cytokine receptors IL-13Ra1 and IL-13Ra2 (LaPorte et al., 2008; Lupardus et al., 2010) . Despite these unanticipated structural similarities between the IL-5 and IL-13 receptor ectodomains, the ligand-binding mechanism differs significantly. The structure of the IL-5:IL-5Ra complex also demonstrates that due to steric hindrance, only one receptor moiety can bind to the homodimeric ligand IL-5 despite the presence of two equivalent receptor-binding sites. In light of the strong efforts currently being made to develop IL-5 antagonists for the treatment of asthma and hypereosinophilic diseases, the structure now provides a detailed picture of the IL-5 ligand-receptor interactions that will fuel the rational design particularly of small-molecule IL-5 inhibitors.
RESULTS

Structure Analysis of the Binary Complex IL-5:IL-5Ra
To gain more insight into IL-5:IL-5R interaction, we prepared the complex of IL-5 bound to the ectodomain of IL-5Ra. After purification, the complex was crystallized and its structure was determined to 2.55 Å resolution (see Table 1 ). The electron density map revealed two ligand-receptor complexes (A and B) in the asymmetric unit (ASU). The receptor IL-5Ra is built from three fibronectin type III (FNIII) domains (D1, D2, and D3), which could be traced from Lys7 to Arg314 in complex A and from Ile8 to Arg314 in complex B (Figure 1 ; see Figures S1 and S2 available online). The ligand forms an intertwined dimer of two four-helix bundles, with the fourth helix of each monomer (M1 and M2) being swapped (Milburn et al., 1993) . For both ligand molecules in the asymmetric unit, IL-5 M1 could be traced from Thr3 to Ile112 and from Pro6 to Glu114 for M2. In total, 8452 protein atoms, six glucose molecules (three per complex), one 2-methyl-2,4-pentanediol (in complex A), and 55 water molecules (32 in complex A, 23 in complex B) could be identified.
The two complexes in the ASU superimpose almost perfectly (root-mean-square deviation [rmsd] 1.1 Å for all Ca atoms, 1.6 Å for all heavy atoms), but some regions deviate significantly (Figure S3 ). The two IL-5Ra ectodomains differ in the b6b7 loop (Gln83 to Leu88) of D1, with the loop being closer to IL-5 by 1.9 Å in complex A. However, as these residues are not in contact with the ligand, these differences have probably only a minor or no effect on ligand binding. Even larger is the difference for the IL-5Ra b1b2 loop (Asp121 to Ser128) of D2, whose backbone shifts up to 8 Å . In complex B this loop approaches IL-5 Thr109 and Glu110 (IL-5 M2), whereas in complex A this loop orients toward the solvent. In addition, the two IL-5 dimers in the ASU exhibit conformational differences. The largest change is observed for the N terminus and the N-terminal half of helix a1 in IL-5 M1 (Glu4 to Glu13). Furthermore, changes are also seen for the C terminus of helix a2, the a2a3 loop, and the start of helix a3 of IL-5 M1 ( Figure S3 ). Because the M1 subunit of IL-5 is not in contact with the receptor IL-5Ra, these changes likely do not directly affect receptor binding.
The Ligand-Binding Domain of IL-5Ra Adopts a Wrench-like Architecture In the structure of the complex, the three FNIII domains 1 (amino acids 7-101), 2 (amino acids 102-217), and 3 (amino acids Laskowski et al. (1993). 218-314) of IL-5Ra wrap around the four-helix IL-5, figuratively speaking, like a wrench around a nut (Figures 1 and 2) . The membrane-proximal D2 and D3 constituting the cytokine recognition motif (CRM) domain share a 100 angle elbow, similar to receptors such as IL-4Ra. Domains 1 and 2 are oriented in a 55 angle instead, resulting in a zigzag-like structure of the IL-5Ra extracellular domain. Contact between IL-5 and the CRM of IL-5Ra is mediated by the loops connecting the seven-stranded b sheets of both FNIII domains, which gather in the hinge region between D2 and D3. Although the structures of D1 and D3 are almost identical, the contact of D1 with IL-5 is made via the side of b strands 4 and 5 by rotating D1 about 30 out of plane compared to D2 and D3. The main contacts of IL-5Ra with IL-5 are formed by the loops b2b3, b4b5, and b6b7 of D3, b3b4 and b6b7 of D2, and strands b4 and b5 of domain D1 (Figures 1 and  2 ). Analysis reveals that although IL-5Ra covers almost 180 on the IL-5 surface, the total buried surface area of IL-5Ra upon binding to IL-5 ($1150 Å 2 ) exceeds that by cytokine receptors exhibiting only a two-FNIII domain CRM architecture such as IL-4Ra ($840 Å 2 ) (Hage et al., 1999) only by 27%. In the complex, both IL-5 monomers of the symmetrical homodimer form contacts with the receptor (Figures 1 and 2 ). The C-terminal end of helix 3, the adjacent b strand 2, and helix 4 of subunit M1 contribute 760 Å 2 interface area, whereas helix 1, the loop ahead of helix 2, and the C terminus of the other subunit M2 form 450 Å 2 of contact area with IL-5Ra. Comparing the structures of free and receptor-bound IL-5 shows that a large induced fit is absent (rmsd 1.2 Å for Ca atoms), suggesting that most of the IL-5Ra epitope in IL-5 is preformed ( Figure S3 ).
IL-5Ra
Shares the Wrench-like Architecture with the IL-13 Receptors a1 and a2 The IL-5Ra receptor is one of the few known cytokine receptors for which it is known that motifs apart from the CRM are essential for ligand binding, with the structurally probably best investi- gated example being gp130 of the IL-6 cytokine family (Boulanger et al., 2003) . Because amino acid sequence homology among the cytokine type I receptor family is quite low, we were surprised that the ectodomain structures of IL5Ra and the IL-13 receptors IL-13Ra1 (LaPorte et al., 2008) and IL-13Ra2 (Lupardus et al., 2010) in their bound conformation in complex with IL-4 and/or IL-13 are highly similar, especially because the ligands IL-13/-4 and IL-5 differ vastly, with IL-13 (as well as IL-4 as a ligand of IL-13Ra1) being a monomer and IL-5 being a dimer ( Figures 3A-3C ). It is even more surprising when the four-helix bundles of IL-5 and IL-13 are structurally compared. Only helix D of both cytokine ligands, which makes the largest contact with the receptor ectodomain, can be structurally aligned (rmsd 0.5 Å for 13 Ca atoms); the interhelical angles between other helices differ by more than 20
. Furthermore, b strand 2 of the short b sheet is different in both ligands, being longer and slightly differently oriented in IL-5 to make larger contact with receptor domain 1. The structures of IL13Ra1 and IL-13Ra2 are, however, highly similar to IL-5Ra, with the seven-stranded b sheets of the N-terminal D1 and D2 overlapping almost perfectly ( Figure S4 ).
In contrast, gp130 receptor architecture is different, with the complex consisting of IL-6, IL-6Ra, and gp130 assembling into a heterohexameric structure ( Figures 3D and 3E ) (Boulanger et al., 2003) . Here, gp130's second and third FNIII domains bind to IL-6 similarly as seen in CRM-like receptor-ligand interaction of other cytokine-receptor interactions such as IL-4:IL-4Ra (Hage et al., 1999) , IL-2:IL-2Rb (Wang et al., 2005) , and hGH:(hGHR) 2 (de Vos et al., 1992) (Figure 3 ). FNIII domain 1 of one gp130, however, ''swaps'' over to the second complex of the hexameric ligand-receptor assembly contacting helix 1, the a1a2 loop, and helix 4 of IL-6 (Boulanger et al., 2003) . In gp130 D1, mainly the N terminus, the b3b4 loop, and strand b7 form the interface with IL-6. Additional stabilization derives from the interaction of the b2b3 and b6b7 loops of gp130 D1 with the four-stranded b sheet in the IL-6Ra N-terminal FNIII domain.
The molecular cause for the different architecture of IL-5Ra/ IL-13Ra1/IL-13Ra2 on the one hand and gp130 on the other hand is probably due to differences in the linker between D1 and D2 ( Figure 3F ). The linker is conserved among IL-5Ra, IL-13Ra1, and IL-13Ra2 with a consensus motif -Pro/ValPro-X 1 -X 2 -(X)-Pro-X 3 -X 4 -X 5 -. Position X 1 or X 2 is filled by a Gly,
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Structure of IL-5 Bound to Its Receptor IL-5Ra and X 3 to X 5 are usually occupied by small residues. The 8-mer stretch forms a U turn with the third Pro at the tip. Although the linker of gp130 looks very similar, a comparison shows that it is two residues shorter compared to IL-5Ra and IL-13Ra1. In gp130, residues following the third Pro are already part of b strand 1 in FNIII domain 2. Thus, all linker residues exhibit backbone torsion angles characteristic for b sheets, whereas corresponding residues -Pro-X 3 -X 4 -in IL-5Ra (Pro105-Gly106-Thr107), IL-13Ra1 (Pro125-Glu126-Ser127), and IL-13Ra2 (Pro136-Glu137-Thr137) have torsion angles characteristic for a-helical or turn-like structures. This feature allows D1 and D2 of IL-5Ra, IL-13Ra1, and IL-13Ra2 to fold on top of each other. In contrast to this, the short linker of gp130 ( Figure 3F ) forces D1 and D2 to arrange in a linear manner. Attempts to vary the linker in IL-13Ra1 by mutating individual residues (or increasing the linker length) led to the loss of IL-13 binding (M. Kraich and T.D.M., unpublished data).
Asymmetric Binding of the Receptor IL-5Ra to Its Dimeric Ligand IL-5 Enforces a 1:1 Stoichiometry The dimeric nature of IL-5 first suggests the existence of two IL-5Ra epitopes. However, biochemical analyses revealed that IL-5 and IL-5Ra interact with a 1:1 stoichiometry (Devos et al., 1993) . Consistently, an engineered monomeric IL-5 binds to IL-5Ra, albeit with 40-fold lower affinity (Li et al., 1997) . With the structure, we can now assign a molecular reason for this finding. Both IL-5Ra epitopes in the dimeric IL-5 molecule are located face to face opposite of the two-fold symmetry axis of IL-5 ( Figure 4 ). However, one IL-5Ra bound to IL-5 already covers parts on both sides of the two-fold axis. This results in a steric clash with the b1b2 loop of IL-5Ra D2, which would protrude far into D1 of a putative second IL-5Ra in a 1:2 IL-5:IL-5Ra model. Consequently, modeling of the complex of IL-5 bound to its IL-5Ra and bc receptors based on the structure of GM-CSF:GM-CSFRa:bc (Hansen et al., 2008) suggests (C) IL-5Ra extracellular domain (D1, blue; D2, green; D3, red) covers more than 170 of the ligand four-helix bundle (gray).
(D) The IL-5 epitope of IL-5Ra (indicated by darker colors; in D1, dark blue; in D2, dark green; in D3, red).
(E) As in (D), but contact residues are color coded by polarity (acidic, red; basic, blue; polar, green; hydrophobic, gray).
(F) The IL-5Ra epitope in IL-5 (color as in D).
(G) As in (E), but for the receptor epitope in IL-5. See also Figure S3 .
Structure of IL-5 Bound to Its Receptor IL-5Ra a 2:2:1 stoichiometry of two (1:1) IL-5:IL-5Ra complexes bound to one dimeric bc. In such a putative model of a ternary complex, bc is located between two IL-5:IL-5Ra assemblies, with the membrane-proximal D3 of IL-5Ra and bc D4 interacting with each other ( Figure 5 ). This model is also supported by biochemical studies using an asymmetrically mutated single-chain IL-5 showing asymmetric receptor recruitment for IL-5Ra and bc (Li et al., 1996) . Remarkably, the contact between IL-5 and bc would be comparably small. More than half of the surface of IL-5 opposite the IL-5Ra-binding face would remain unburied in the putative ternary assembly, raising the question of why IL-5, unlike the other bc binders GM-CSF and IL-3, exists as a dimeric molecule ( Figure 5 ).
The IL-5Ra Structural Epitope Is Formed by Three Independent Patches Three IL-5-contacting patches can be identified in IL-5Ra: the b2b3, b4b5, and b6b7 loops of D3, the b3b4 and b6b7 loops of D2, and strands b3 and b4 of D1 (Figures 1 and 2 ; Figure S5 ). In IL-5, interface residues cluster in the C terminus of helix a3, b strand 2 between helices 3 and 4, which runs antiparallel to b strand 4 of IL-5Ra D1, and helix 4 of monomer 1. In IL-5, M2 residues in the N-terminal half of helix 1, residues in b strand 1, and the C terminus contact IL-5Ra (Figures 1 and 2 ). Interactions in patch 1 between b strand 2 in M1 of IL-5 and b strand 4 in D1 of IL-5Ra are dominated by polar bonds, harboring 11 out of 15 total intermolecular hydrogen bonds ( Figure 6A ; Table S1 ). The charge distribution between ligand and receptor is highly asymmetric, resulting in strong charge-charge complementarities between D1 of IL-5Ra and the IL-5 a3a4 loop (Figures S5 and S6) . Three consecutive residues, Arg90, Arg91, and Arg92, form a positive patch in the a3a4 loop of IL-5, with Asp55, Asp56, and Glu58 forming the complementary negative patch in IL-5Ra. Besides IL-5 Arg91 forming a salt bridge with IL-5Ra Asp55, other charged residues in the a3a4 loop of IL-5, Glu89, Arg90, and Arg92 are also part of the H-bond network. The latter act as a polar ''zipper'' forming eight direct intermolecular H bonds with Ser64, Glu44, Glu58, Asp55, and Glu54 of IL-5Ra. Four H bonds originate from Arg90 of IL-5, including a bidentate main chain-main chain H bond to Glu58 of IL-5Ra and two salt bridges between the guanidine group of Arg90 of IL-5 and the carboxyl groups of Glu44 and Glu58 of IL-5Ra. Several of these 11 intermolecular H bonds are located at the solvent-accessible interface surface, but their embedding in a large H-bond network of 29 intra-and intermolecular H bonds possibly suggests a large overall binding energy contribution. Interestingly, the structural Whereas a conserved sequence -Pro-Pro-small-X-Pro-is observed in both IL-5Ra and gp130, additional residues in IL-5Ra (marked in magenta) allow D1 to fold over D2. See also Figure S4 . (C) The overlap is due to D2 of IL-5Ra, specifically the long b1b2 loop.
Structure of IL-5 Bound to Its Receptor IL-5Ra similarities in the wrench-like architecture between IL-5Ra and IL-13Ra1/a2 are also reflected in a similar interaction of domain 1 of the IL-13 receptors with the ligand IL-13 ( Figure S4 ). In the complexes, b strand 4 of the receptors and the ligands' b strand 2 all share a main chain-main chain H bond; various additional polar bonds strengthen this conserved interaction, possibly via a cooperative mechanism. However, there are far fewer polar bonds between D1 of IL-13Ra1/a2 and the ligand IL-13 compared to the IL-5:IL-5Ra interaction. Furthermore, the ''affinity-maturated'' IL-13Ra2, which exhibits a drastically increased affinity to IL-13, does not form an increased number of intermolecular H bonds with IL-13 via D1. It seems that here the affinity is increased due to more hydrophobic and polar interactions in site II equivalent to patch 2. Patch 2 consists of D2 (b3b4 and b6b7 loops) of IL-5Ra, which interacts with the a1a2 loop and the C terminus of IL-5 M2 (Figures 1, 2 , and 6B). Although several residues are of polar or charged character, only one H bond exists between IL-5 Lys39 and the backbone of Arg188 of IL-5Ra. Arg188 of IL-5Ra was suggested to be important for IL-5 binding ; however, it is not only the polar character but also the hydrophobic interaction of the Arg188 side chain with Val106 and Thr109 of IL-5 that contributes to binding. Its positive charge is neutralized by Glu110 of IL-5 M1, which was identified as a main binding determinant of IL-5 (Morton et al., 1995 ), but there is no H bond between IL-5 Glu110 and IL-5Ra Arg188. Thus, as Arg188 is completely buried inside the interface, loss of the negative charge possibly leads to repulsive electrostatic forces. Another hydrophobic binding determinant is IL-5Ra Trp158 in the b3b4 loop, which contacts Trp111 and Ile112 of IL-5 M1. Because most intermolecular interactions in patch 2 are medi- ated only by side chain-side chain contacts, patch 2 seems less tightly packed compared to patch 1. Patch 3 comprises D3 of IL-5Ra, namely the b2b3, b4b5, and b6b7 loops, which pack against the C-terminal half of helix 4 of IL-5 subunit M1 and helix 1 of IL-5 subunit M2 (Figures 1, 2 , and 6C). Patch 3 adds the least buried surface area (276 Å 2 of IL-5Ra and 430 Å 2 of IL-5), and it might thus be assumed that it contributes less to the overall binding energy. Indeed, a truncated IL-5Ra lacking D3 still binds weakly to IL-5, whereas deletion of D1 in IL-5Ra abrogates IL-5 binding completely (data not shown). Most interactions here are hydrophobic (Figures 1, 2 , and 6C). The C-terminal half of IL-5 M1 helix 4 packs against a hydrophobic area in IL-5Ra, with the disulfide bond between Cys249 and Cys296 in the center. Interestingly, IL-5Ra Arg297, a proposed hot spot of IL-5 binding , makes almost no contact with IL-5. Its importance for binding is due to an intramolecular salt bridge with IL-5Ra Asp217, thereby stabilizing the hinge angle between D2 and D3. Mutation of Arg297 might affect the orientation of both domains, leading to loss of binding.
The Functional Ligand-Receptor Epitope of the IL-5:IL-5Ra Complex
Previous mutagenesis studies revealed several residues of IL-5 and IL-5Ra that are functionally important for the interaction ( Figures 6D and 6E) . The early studies performed by the groups of Jan Tavernier and Walter Fiers at Roche (Cornelis et al., 1995; Tavernier et al., 1995) and Timothy Wells at Glaxo (Graber et al., 1995) did not employ surface plasmon resonance or calorimetry to determine the energy contribution. However, their results derived from cell-based binding assays, proliferation, or competition binding analysis clearly identified Glu89, Arg91, and Trp111 as main binding determinants of IL-5 and His38, Lys39, His41, Thr109, and Glu110 as of significant but minor importance for
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IL-5Ra binding (Table S2 ; Figure 6E ). Based on the structure, it now becomes evident that IL-5 His38, His41, and Trp111 seem to stabilize the structure or ''orient'' side chains of other residues in IL-5, thereby contributing to binding IL-5Ra. His38 and His41 help to stabilize the IL-5 a2a3 loop and orient Lys39, which then interacts via an H bond with the carbonyl of IL-5Ra Arg188. Similarly, IL-5 Trp111 is important for the structural integrity of the C terminus of helix 4. Nonconservative exchanges likely lead to local unwinding, thereby destroying favorable interactions of the nearby Glu110 and of van der Waals interactions of helix 4 with the b6b7 loop of IL-5Ra D3 ( Figure 6C ). Several studies also analyzed the role of important residues in IL-5Ra (Cornelis et al., 1995; Ishino et al., 2004) showing that polar bonds dominate the interaction between IL-5Ra D1 and IL-5. Alanine mutagenesis of the two main binding determinants Asp55 (K D 156-fold increased) and Asp56 (K D 17-fold increased destroys the H-bond network with Arg91 and Gln95 (both to Asp55 of IL-5Ra) as well as Arg32 and Arg92 (to Asp56 of IL-5Ra) of IL-5. Our data (Table S3) show that maintaining the negative charge in the variant D55E partially attenuates the loss of binding (K D 14-fold increased). The main chain-main chain H bond between Glu58 of IL-5Ra and Arg90 of IL-5 is conserved in the interaction between IL-4/IL-13 and IL-13Ra1 ( Figure S4 ) and is absolutely crucial for binding (IL-5Ra E58P K D R2000-fold increased). In contrast, H bonds between their side chains do not contribute significantly . Tyr57 of IL-5Ra was also identified as a hot spot of binding (Cornelis et al., 1995) . Exchange to alanine leads to an almost complete loss of binding. This large effect can be explained by favorable p-p stacking interactions of the aromatic ring and the guanidine group of IL-5 Arg91, which possibly stabilize the salt bridge between IL-5 Arg91 and IL-5Ra Asp55 ( Figure 6A ). Accordingly, replacement of Tyr57 by phenylalanine does not decrease IL-5 affinity significantly (4.5-fold). The highly cooperative H-bond network is exemplified by the alanine replacement of IL-5Ra Ser64 ($60-fold loss in affinity), which coordinates the orientation of IL-5Ra Tyr57 as well as IL-5 Glu89, which interacts with IL-5 Arg91.
Outside IL-5Ra D1, very few residues are described that play a role in the IL-5:IL-5Ra interaction (Table S3 ; Figure 6D ). Ishino et al. (2004) identified Arg188 in IL-5Ra D2 as a main binding determinant. Further contribution to IL-5 binding comes from Lys186 (D2) and Arg297 (D3). However, only IL-5Ra Lys186 engages in an H bond with IL-5 Glu110, whereas IL-5Ra Arg188 shares hydrophobic contacts with Gly105, Val106, and Thr109 of IL-5. Additionally, through its intramolecular H bond with the carbonyl of Cys296, Arg188 likely orients the IL-5Ra D3 b6b7 loop. Mutation of Arg188 to lysine thus results in a similar reduction in affinity as for R188A, as the shorter side chain results in the loss of this H bond. Arg297 of IL-5Ra acts similarly, as it makes no contact with IL-5, but also stabilizes the IL-5Ra D3 b6b7 loop via an intramolecular H bond with Asp217.
As there are almost no intermolecular H bonds involving the side chains of D2 and D3 of IL-5Ra, it seems that contribution of the polar residues by their side chains to IL-5 binding is limited (Table S3 ; Figure 6D ). However, the number of hydrophobic contacts between IL-5Ra and IL-5 making favorable van der Waals contacts is also small. Only Trp158 and Met295 of IL-5Ra share significant contact area. Mutation W158A reduces the affinity for IL-5 19-fold, and M295A decreases the affinity 9-fold. Further van der Waals contacts in the interface involve the main chain of IL-5Ra, thereby highlighting the importance of residues (Ile183, Arg297) that maintain the receptor loop conformation.
The Wrench-like Architecture of IL-5Ra Is Possibly Preformed The structure of IL-5Ra raises the question of whether its architecture is preformed or whether the ''wrench'' closes only upon binding to IL-5 ( Figure 7A ). The contact of IL-5 with all FNIII Tables S1-S3. domains of IL-5Ra covers more than 170 of the IL-5 torus, and thus opening and closing of the wrench would on the one hand facilitate complex formation; on the other hand, several observations also argue against a ligand-induced opening/closing mechanism. First, residues in the D1-D2 interface are conserved in IL-5Ra of different species as well as in the structurally related receptors IL-13Ra1 and IL-13Ra2 ( Figures 7B and 7C) . Second, replacement of one of the conserved residues in the linker region of IL-13Ra1 (see above) or changing the length of the linker abrogated binding of IL-13 completely (M. Kraich and T.D.M., unpublished data). We thus mutated several residues that either share hydrophobic contacts or are involved in H bonds between D1 and D2. Four residues seem to occupy key positions: Leu23, Ile69, and His71 in D1 and Asp208 in D2 of IL-5Ra ( Figure 7B ). Residue Asp208 in b strand 8 of D2 is completely buried in the D1-D2 interface. Its carboxylate group forms two H bonds with the amides of Leu70 and His71 (in D1). Because Asp208 is completely shielded by Leu23, Ile69, and His71 of D1 and Leu194, Pro206, and Leu210 of D2, these H bonds presumably (help to) orient D1 and D2 ( Figure 7B ). Mutation of any of these residues should thus disrupt the architecture, thereby abrogating binding. Indeed, mutations L23A and D208A abrogate IL-5 binding completely, whereas IL-5Ra H71A could not even be refolded. Estimating the K D on the basis of the upper surface plasmon resonance measurement limits suggests a K D for L23A or D208A larger than 5mM. Thus, the affinity is decreased at least 2500-fold (Table S3) . Exchange of IL-5Ra Ile69 to alanine has the ''smallest'' impact, with a 550-fold affinity loss. The loss of IL-5 binding due to mutations in the IL-5Ra D1-D2 interface suggests that either the ligand binding via an initially open wrench architecture is highly cooperative with the interactions between IL5Ra D1 and the ligand on one side and the interactions in the D1-D2 interface being coupled or that the wrench is preformed and destabilization of this ''closed'' architecture leads to the observed loss of IL-5 binding. However, together with the observation that changes in the linker also lead to loss of ligand binding in IL-13Ra1, another piece of experimental evidence hints to the latter mechanism of a preformed wrench architecture. The decrease in affinity observed for I69A is solely due to a strongly reduced association rate k on (k on (var.)/k on (WT) = 2.7 3 10 À3 ), whereas the dissociation rate k off is unaltered (k off (var.)/k off (WT) = 1.5) ( Figure 7D ). The slower association might be explained by the opening and closing of the destabilized wrench being the rate-limiting step of IL-5 binding and much slower than it would be via a preformed wrench architecture. The almost unaltered dissociation rate points toward the complex stability (i.e., the complex lifetime) being the same as for the wild-type proteins and that the D1-D2 interface interactions are likely not just contributing in a cooperative binding mechanism. However, to finally solve this puzzle, structural data for the unbound ectodomain of IL-5Ra are needed.
DISCUSSION
IL-5 and GM-CSF belong to the cytokine family sharing the bc receptor, and their a receptors show reasonable amino acid sequence homology. Recently, the structure of the ternary ligand-receptor complex GM-CSF:GM-CSFRa:bc has been determined (Hansen et al., 2008) . In this structure, a large part of the receptor GM-CSFRa is unstructured and not modeled ( Figure 8A ). In the structure, only GM-CSFRa FNIII domain 3 from Phe196 to Gly294 is ordered. For D2 only a small part is observed, including a two-stranded b sheet corresponding to strands 1 and 2 and a short structure matching the b6b7 loop of IL-5Ra D2. Domain 1 is completely absent from the model (in Hansen et al., D1 is called the ''knob'' and D2 and D3 are numbered D1 and D2, respectively). SDS-PAGE analysis of crystals proved the presence of the full ternary complex with all components seemingly intact. Thus, Hansen et al. concluded that D1 of GM-CSFRa would be disordered. This is in contrast to the highly defined wrench architecture of IL-5Ra with all three domains in tight contact with the ligand (Figures 1 and 2 ). One conclusion would be a diversity in the architectures of the a subunits of bc cytokine family members IL-3Ra, GM-CSFRa, and IL-5Ra regardless of the similarities in sequence. However, a sequence alignment ( Figure S7 ) of these receptor ectodomains together with IL-13Ra1 (LaPorte et al., 2008) shows that the sequences encoding the b strands in the three FNIII domains are conserved, suggesting a similar secondary structure in GM-CSFRa and IL-3Ra ( Figures 8A and 8B) . Furthermore, D1 of GM-CSFRa contains five cysteines presumably involved in disulfide bridges, arguing against intrinsic disorder. From the sequence alignment we modeled disulfide bonds for GMCSFRa, suggesting disulfides between Cys29 and Cys65, and Cys38 and Cys57, in D1 ( Figure 8C ). Based on this model Cys59 would be unpaired, possibly sharing a similar role with Cys66 in IL-5Ra. Several favorable interactions could be predicted between the modeled D1 of GM-CSFRa and GM-CSF. The distribution of charged residues in the putative ligand interface of D1 of GM-CSFRa (mainly positively charged amino acids, e.g., Lys44 and Arg46) and helix 4 of GM-CSF (negatively charged amino acids, e.g., Glu104 and Glu108) would also support a ligand-receptor architecture as in IL-5:IL-5Ra (Figure 8D) . Moreover, the interface between D1 and D2 (see above), which likely preforms the wrench-like architecture (see above), is conserved in IL-5Ra, GM-CSFRa, and IL-3Ra. The aspartate residue in D2 (Asp208 in IL-5Ra), which possibly orients D1 and D2 by H bonds, is conserved in GM-CSFRa (Asp185) and IL-3Ra.
Very recent mutagenesis data support the assumption for a common architecture of the receptor a subunits IL-3Ra, IL-5Ra, and GM-CSFRa (Mirza et al., 2010) . Mutation of Val51, Arg54, and in particular Cys59 in GM-CSFRa abrogates GM-CSF binding. Similarly, deletion of D1 in IL-3Ra and the GM-CSFRa/IL-3Ra chimera have shown that N-terminal D1 is required for high-affinity binding of IL-3 and that corresponding residues of GM-CSFR cannot substitute (Barry et al., 1997; Rapoport et al., 1996) . Whether the ternary complex formation triggers a rearrangement in the interdomain architecture cannot be answered at present. However, the structure of IL-13Ra1 in the complexes bound to the monomeric cytokine IL-4 or IL-13 (LaPorte et al., 2008; Lupardus et al., 2010) , which is highly similar to IL-5Ra (Figure 3 ; Figure S4 ), suggests that the wrench-like architecture does not arise from the unique homodimeric nature of IL-5.
Although the role of eosinophils in asthma is still under debate (Nair et al., 2009; Wenzel, 2009) , the attenuation of symptoms in hypereosinophilic diseases upon removal of eosinophils by approaches targeting IL-5 clearly fortifies IL-5 as an interesting and important drug target for such endeavors (Rothenberg et al., 2008) . With the aid of the structure of the IL-5:IL-5Ra complex, small-molecule-and peptide-based inhibitors that impede IL-5 binding to IL-5Ra can be rationally designed. For the cyclic peptide AF17121, an IL-5-inhibiting mechanism was proposed assuming the structural similarity of this peptide to the IL-5 a3a4 turn (Ruchala et al., 2004) . However, that several residues of this peptide lack similarity with IL-5 but are nevertheless important for interaction suggests that its binding to IL-5Ra is more complex. Isothiazolone derivatives inhibit IL-5 signaling by covalent modification of the free thiol of Cys66 in IL-5Ra (Devos et al., 1994) . Our own studies show that small thiol-reactive compounds such as mercaptoethanol are tolerated in ligand binding. Cys66 is located within the interface in a water-filled pocket with a 6-7 Å gap to IL-5, thereby explaining why only larger compounds inhibit IL-5 binding efficiently. Also, small IL-5-inhibiting compounds that do not interfere via covalent attachment to Cys66 could be identified. Whereas for inhibitory isoflavones and chalcones the inhibition mechanism cannot be linked to direct binding to either IL-5Ra or IL-5 (Min et al., 1999; Yang et al., 2007) , a quinoxaline derivative, YM-90709, has been shown to directly interfere with the IL-5:IL-5Ra interaction and block receptor activation with a submicromolar IC 50 (Morokata et al., 2002) . However, no molecular details of this interaction are known thus far. The new structure of the IL-5:IL-5Ra complex thus now provides the necessary insights into the ligand-receptor recognition and will likely facilitate rational design to improve anti-IL-5 therapeutics for their application in the treatment of allergic asthma and hypereosinophilic diseases.
EXPERIMENTAL PROCEDURES
Preparation of Human IL-5 Human IL-5 was expressed and purified from Escherichia coli as described (Proudfoot et al., 1990) . IL-5 was extracted from inclusion bodies and prepurified by gel filtration using 6 M guanidine hydrochloride, 10 mM sodium acetate (pH 4.5) as running buffer before renaturation. The IL-5 protein was subsequently refolded by a multistep protocol as described (Proudfoot et al., 1990) . After refolding, the protein was concentrated to 5 mg/ml and purified by gel filtration using a HiLoad 16/60 Superdex column. IL-5 variants were prepared using QuikChange methodology (Stratagene). The correctness of the IL-5 mutant proteins was verified by sequencing of the expression plasmid cDNA and subsequently on a protein level by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry.
Preparation of the Extracellular Domain of Human IL-5Ra
The soluble splice variant of human IL-5Ra comprising Asp1 to Arg314 was cloned into the pET3d vector and expressed in the E. coli strain Rosetta(DE3) by a modified protocol (Monahan et al., 1997; Murata et al., 1992) . IL-5Ra was isolated from inclusion bodies. For refolding, denatured IL-5Ra was diluted with refolding buffer consisting of 7.5 M urea, 50 mM Tris-HCl (pH 9.5), 0.1 mM cysteine to a concentration of 100 mg/ml. First, this refolding solution was dialyzed against 10 volumes of 3 M urea, 50 mM Tris-HCl (pH 9.5), 100 mg/l CuSO 4 for 24 hr. The urea concentration was then lowered every 24 hr by exchanging 50% of the dialysis buffer with 50 mM Tris-HCl (pH 9.5) until a urea concentration of 0.75 M was obtained. Refolding was stopped by dialysis against 50 mM Tris-HCl (pH 8.1). IL-5Ra was purified by anionexchange chromatography (Q-Sepharose) using a linear gradient from 0 to 0.5 M NaCl in 50 mM Tris-HCl (pH 8.1). Dimeric IL-5Ra and higher-molecular-weight aggregates were removed by affinity chromatography using an IL-5 affinity matrix. Variants were prepared using the QuikChange methodology (Stratagene), and mutations were verified by DNA sequencing. Purity and homogeneity of IL-5Ra proteins were analyzed by SDS-PAGE, analytical reverse-phase HPLC, and mass spectrometry.
Preparation and Crystallization of the Binary Ligand-Receptor Complex IL-5:IL-5Ra
The complex of IL-5:IL-5Ra was prepared by mixing the proteins at an equimolar ratio and subsequent gel filtration using 10 mM Tris-HCl (pH 8.1), 150 mM NaCl as buffer. Fractions containing the complex were combined and concentrated to 10 mg/ml in 10 mM Tris-HCl (pH 8.1). Crystals were obtained by vapor diffusion (sitting-or hanging-drop) from various conditions of commercial kits (e.g., Hampton crystal screens 1 and 2, PEG/ion screen, as well as JBS screens 4 and 5 of Jena Bioscience). All of the initial crystallization conditions were unsuitable for data collection due to needle cluster formation. Mutating Cys66 of IL-5Ra to alanine improved reproducibility and yielded single crystals. Final additive screening and optimization of the crystallization buffer composition provided crystals of suitable size (400 3 200 3 50 mm) growing from 10% PEG 20000, 20% glucose, 0.1 M MOPS (pH 6.5), 2.5% 2,4-methylpentanediol using a hanging-drop setup and a protein:precipitant ratio of 1:1 in the droplet within 3-5 days.
Data Collection and Structure Determination
We solved the structure using a seleno-multiwavelength anomalous dispersion approach. To increase the number of methionine residues, four mutations were introduced into IL-5RaC66A: K72M, L138M, K167M, and L234M, referred to as IL-5RaCM4. SeMet-derivatized IL-5 and IL-5RaCM4 were prepared by expression in E. coli B834(DE3), which were grown in M9 minimal medium supplemented with 50 mg/l DL-selenomethionine. Protein purification, complex preparation, and crystallization were performed as described above. Anomalous data were acquired at 100K at three wavelengths from a single crystal of Se-IL-5:Se-IL-5RaCM4 (peak, inflection, and remote) using beamline XS10 SA (Swiss Light Source, Switzerland) and a 235 sweep with a 1 s exposure per frame and a 1 oscillation. Diffraction data were complete to a resolution of 2.55 Å for peak and remote and to 2.8 Å for the inflection wavelength. Data were processed using CrystalClear (Rigaku), seleno-atom positions were determined using SHELX (Sheldrick, 2008) , and refinement and phasing were performed using SHARP/autoSHARP (Vonrhein et al., 2007) . The initial experimental electron density map was traced automatically using ARP/WARP (Perrakis et al., 1999) to provide an initial template for manual model building. Refinement was completed using experimental phases throughout refinement and REFMAC version 5.02 (Murshudov et al., 1997) (for statistics, see Table 1 ).
Surface Plasmon Resonance Analysis
Surface plasmon resonance experiments were performed using a Biacore 2000 system (GE Healthcare). Data were evaluated using the software BIAevaluation (version 2.2.4). All measurements were performed at 294K using HBS150 buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20). A CM5 sensor chip was coated with about 3000 resonance units (1 RU = 1 pg mm À2 ) streptavidin (Sigma) by amino coupling using Nhydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. For immobilization, IL-5 was biotinylated with a 2-fold molar excess (protein:biotin) of NHS-LC-biotin (Pierce) according to the manufacturer's recommendation and then captured on the streptavidin chip to a density of maximal 300 RU. To analyze binding, six different analyte concentrations were used, usually ranging from 0.13 to 103 of the K D value determined in the experiment. Bulk effects were corrected by subtracting a sensorgram of a control flow cell from all other sensorgrams. The biosensor was regenerated by application of a short pulse (30 s) of 4 M MgCl 2 . The data were fitted to a 1:1 Langmuir-type interaction model, and the K D values were calculated from the fitted kinetic rate constants k on (association rate) and k off (dissociation rate). All affinities are termed ''apparent'' K D s, indicating that the absolute values might differ from values obtained by other methods. However, in a direct comparison of values obtained under these conditions, a difference of more than 2-fold is considered significant.
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